WuXi Testing: End-to-End Testing Platform for All Modalities
Discovery
Pre-Clinical
Small Molecule
Biologics, Cell / Gene Therapy
WuXi Chemistry & WuXi Biologics
Pre-Clinical Testing
WuXi
Testing
Clinical Testing
Commercial
Clinical
WIND (WuXi IND)
DMPK
Toxicology
Bioanalysis
Medical Device Testing
Clinical CRO
Clinical SMO
2
WuXi Testing: A Global Platform from Preclinical to Clinical
Employees
Clients1
Projects2
9,300+
2,200+
8,800+
•
3,500+
Pre-clinical
•
2,100+ Pre-clinical
•
5,500+
Pre-clinical
•
5,800+
Clinical
•
800+ Clinical
(Including 140 WIND)
•
3,300+
Clinical
Note: 1. Active client with PO award
2. Active projects with PO award ( Multiple projects may cover single molecule) Data from: Jul 2021 to Jun 2022
3
WuXi Testing: Robust Track Record & Growth Forecast
+29%
2018A
2019A
2020A
2021A
H2
H1
2022E
4
WuXi Testing: Business Performance by Division
Lab Testing Business
+39%
H2
H1
2018A
2019A
2020A
2021A
2022E
SMO Business
+23%
H2
H1
2018A
2019A
2020A
2021A
2022E
WuXi Clinical Business
-8%
H2
H1
2018A
2019A
2020A
2021A
2022E
5
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
Original Link
Original Document
Permalink
Disclaimer
WuXi AppTec Co. Ltd. published this content on 27 July 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 27 July 2022 09:41:05 UTC.
WuXi AppTec Co., Ltd. specializes in providing a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical and biotech industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. Net sales break down by activity as follows:
- laboratory services (60.9%): small molecules discovery services, bioanalytical services, medical devices safety testing services, comprehensive manufacturing and testing services for cell and gene therapies, etc.;
- CMO and CDMO services (31.9%): development of manufacturing processes, production of advanced intermediates and active pharmaceutical ingredients, formulation development and dosage drug product manufacturing, for preclinical and clinical trials, new drug application, and commercial supply of chemical drugs, etc.;
- clinical research services (7.1%): project planning, clinical operation and monitoring and managements of phase I-IV clinical trials, medical device trials, etc.;
- other (0.1%).
Net sales are distributed geographically as follows: China (25.1%), Asia (4.1%), the United States (53.6%), Europe (16%) and other (1.2%) .